1. Home
  2. INTS vs IRD Comparison

INTS vs IRD Comparison

Compare INTS & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • IRD
  • Stock Information
  • Founded
  • INTS 2012
  • IRD 2018
  • Country
  • INTS United States
  • IRD United States
  • Employees
  • INTS N/A
  • IRD N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • INTS Health Care
  • IRD
  • Exchange
  • INTS Nasdaq
  • IRD NYSE
  • Market Cap
  • INTS 33.4M
  • IRD 36.0M
  • IPO Year
  • INTS 2023
  • IRD N/A
  • Fundamental
  • Price
  • INTS $2.13
  • IRD $1.14
  • Analyst Decision
  • INTS Strong Buy
  • IRD Strong Buy
  • Analyst Count
  • INTS 3
  • IRD 1
  • Target Price
  • INTS $8.50
  • IRD $8.00
  • AVG Volume (30 Days)
  • INTS 35.4K
  • IRD 144.6K
  • Earning Date
  • INTS 03-13-2025
  • IRD 02-19-2025
  • Dividend Yield
  • INTS N/A
  • IRD N/A
  • EPS Growth
  • INTS N/A
  • IRD N/A
  • EPS
  • INTS N/A
  • IRD N/A
  • Revenue
  • INTS N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • INTS N/A
  • IRD N/A
  • Revenue Next Year
  • INTS N/A
  • IRD $29.37
  • P/E Ratio
  • INTS N/A
  • IRD N/A
  • Revenue Growth
  • INTS N/A
  • IRD N/A
  • 52 Week Low
  • INTS $1.50
  • IRD $0.81
  • 52 Week High
  • INTS $5.94
  • IRD $2.71
  • Technical
  • Relative Strength Index (RSI)
  • INTS 42.33
  • IRD N/A
  • Support Level
  • INTS $2.20
  • IRD N/A
  • Resistance Level
  • INTS $2.53
  • IRD N/A
  • Average True Range (ATR)
  • INTS 0.33
  • IRD 0.00
  • MACD
  • INTS -0.01
  • IRD 0.00
  • Stochastic Oscillator
  • INTS 36.76
  • IRD 0.00

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: